Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 10 de 10
Filter
1.
Mol Cancer Res ; 15(10): 1318-1330, 2017 10.
Article in English | MEDLINE | ID: mdl-28710231

ABSTRACT

Tuberous sclerosis complex (TSC) is a tumor-suppressor syndrome affecting multiple organs, including the brain, skin, kidneys, heart, and lungs. TSC is associated with mutations in TSC1 or TSC2, resulting in hyperactivation of mTOR complex 1 (mTORC1). Clinical trials demonstrate that mTORC1 inhibitors decrease tumor volume and stabilize lung function in TSC patients; however, mTOR inhibitors are cytostatic not cytocidal, and long-term benefits and toxicities are uncertain. Previously, we identified rapamycin-insensitive upregulation of cyclooxygenase 2 (PTGS2/COX2) and prostaglandin E2 (PGE2) production in TSC2-deficient cells and postulated that the action of excess PGE2 and its cognate receptors (EP) contributes to cell survival. In this study, we identify upregulation of EP3 (PTGER3) expression in TSC2-deficient cells, TSC renal angiomyolipomas, lymphangioleiomyomatosis lung nodules, and epileptic brain tubers. TSC2 negatively regulated EP3 expression via Rheb in a rapamycin-insensitive manner. The EP3 antagonist, L-798106, selectively suppressed the viability of TSC2-deficient cells in vitro and decreased the lung colonization of TSC2-deficient cells. Collectively, these data reveal a novel function of TSC2 and Rheb in the regulation of EP3 expression and cell viability.Implications: Therapeutic targeting of an aberrant PGE2-EP3 signaling axis may have therapeutic benefit for TSC patients and for other mTOR-hyperactive neoplasms. Mol Cancer Res; 15(10); 1318-30. ©2017 AACR.


Subject(s)
Mechanistic Target of Rapamycin Complex 1/metabolism , Ras Homolog Enriched in Brain Protein/metabolism , Receptors, Prostaglandin E, EP3 Subtype/metabolism , Tumor Suppressor Proteins/metabolism , Angiomyolipoma/genetics , Angiomyolipoma/metabolism , Animals , Brain/metabolism , Cell Line, Tumor , Cell Survival/drug effects , Child , Child, Preschool , Epilepsy/genetics , Epilepsy/metabolism , Female , Humans , Infant , Kidney Neoplasms/genetics , Kidney Neoplasms/metabolism , Lung Neoplasms/genetics , Lung Neoplasms/metabolism , Lymphangioleiomyomatosis/genetics , Lymphangioleiomyomatosis/metabolism , Male , Mice , Mutation , Sulfonamides/administration & dosage , Sulfonamides/pharmacology , Tuberous Sclerosis Complex 2 Protein , Tumor Suppressor Proteins/deficiency , Up-Regulation
2.
JCI Insight ; 1(19): e86629, 2016 Nov 17.
Article in English | MEDLINE | ID: mdl-27882343

ABSTRACT

Lymphangioleiomyomatosis (LAM) is a progressive lung disease that primarily affects young women. Genetic evidence suggests that LAM cells bearing TSC2 mutations migrate to the lungs, proliferate, and cause cystic remodeling. The female predominance indicates that estrogen plays a critical role in LAM pathogenesis, and we have proposed that estrogen promotes LAM cell metastasis by inhibition of anoikis. We report here that estrogen increased LAM patient-derived cells' resistance to anoikis in vitro, accompanied by decreased accumulation of the proapoptotic protein Bim, an activator of anoikis. The resistance to anoikis was reversed by the proteasome inhibitor, bortezomib. Treatment of LAM patient-derived cells with estrogen plus bortezomib promoted anoikis compared with estrogen alone. Depletion of Bim by siRNA in TSC2-deficient cells resulted in anoikis resistance. Treatment of mice with bortezomib reduced estrogen-promoted lung colonization of TSC2-deficient cells. Importantly, molecular depletion of Bim by siRNA in Tsc2-deficient cells increased lung colonization in a mouse model. Collectively, these data indicate that Bim plays a key role in estrogen-enhanced survival of LAM patient-derived cells under detached conditions that occur with dissemination. Thus, targeting Bim may be a plausible future treatment strategy in patients with LAM.


Subject(s)
Anoikis , Bcl-2-Like Protein 11/metabolism , Estrogens/physiology , Lung Diseases/pathology , Lymphangioleiomyomatosis/pathology , Tumor Suppressor Proteins/genetics , Animals , Bortezomib/pharmacology , Female , Humans , Lung/cytology , Mice , Mice, SCID , Tuberous Sclerosis Complex 2 Protein , Tumor Cells, Cultured
3.
Cell Signal ; 28(12): 1904-1915, 2016 12.
Article in English | MEDLINE | ID: mdl-27634387

ABSTRACT

The major biological function of mitochondria is to generate cellular energy through oxidative phosphorylation. Apart from cellular respiration, mitochondria also play a key role in signaling processes, including aging and cancer metabolism. It has been shown that S6K1-knockout mice are resistant to obesity due to enhanced beta-oxidation, with an increased number of large mitochondria. Therefore, in this report, the possible involvement of S6K1 in regulating mitochondria dynamics and function has been investigated in stable lenti-shS6K1-HeLa cells. Interestingly, S6K1-stably depleted HeLa cells showed phenotypical changes in mitochondria morphology. This observation was further confirmed by detailed image analysis of mitochondria shape. Corresponding molecular changes were also observed in these cells, such as the induction of mitochondrial fission proteins (Drp1 and Fis1). Oxygen consumption is elevated in S6K1-depeleted HeLa cells and FL5.12 cells. In addition, S6K1 depletion leads to enhancement of ATP production in cytoplasm and mitochondria. However, the relative ratio of mitochondrial ATP to cytoplasmic ATP is actually decreased in lenti-shS6K1-HeLa cells compared to control cells. Lastly, induction of mitophagy was found in lenti-shS6K1-HeLa cells with corresponding changes of mitochondria shape on electron microscope analysis. Taken together, our results indicate that S6K1 is involved in the regulation of mitochondria morphology and function in HeLa cells. This study will provide novel insights into S6K1 function in mitochondria-mediated cellular signaling.


Subject(s)
Mitochondria/metabolism , Ribosomal Protein S6 Kinases, 70-kDa/metabolism , Adenosine Triphosphate/metabolism , Carbonyl Cyanide m-Chlorophenyl Hydrazone/pharmacology , HeLa Cells , Humans , Intracellular Space/metabolism , Mitochondria/drug effects , Mitochondrial Dynamics/drug effects , Mitophagy/drug effects , Oxygen Consumption/drug effects , RNA, Small Interfering/metabolism , Reactive Oxygen Species/metabolism , TOR Serine-Threonine Kinases/metabolism
4.
Oncol Rep ; 28(3): 931-6, 2012 Sep.
Article in English | MEDLINE | ID: mdl-22711061

ABSTRACT

Mitogen-activated protein kinase phosphatase 5 (MKP-5)/DUSP10 acts as a phosphatase of stress-activated kinases (JNK and p38), but its activity towards ERK has not been demonstrated. In the present study we observed that MKP-5 interacts with ERK, retains it in the cytoplasm, suppresses its activation and downregulates ERK-dependent transcription. These data suggested a novel MKP-5 function as a scaffold protein for the ERK pathway. We analyzed MKP-5 gene expression in several tumors, and found that it is frequently upregulated in colorectal but not in lung and breast cancer, suggesting its association with the malignant phenotype of colon cancer.


Subject(s)
Carcinoma/enzymology , Colonic Neoplasms/enzymology , Dual-Specificity Phosphatases/metabolism , Extracellular Signal-Regulated MAP Kinases/metabolism , Gene Expression Regulation, Enzymologic , Gene Expression Regulation, Neoplastic , Mitogen-Activated Protein Kinase Phosphatases/metabolism , Cell Line, Tumor , Dual-Specificity Phosphatases/genetics , Genes, Reporter , Humans , JNK Mitogen-Activated Protein Kinases/metabolism , Luciferases/biosynthesis , Luciferases/genetics , MAP Kinase Signaling System , Mitogen-Activated Protein Kinase Phosphatases/genetics , Phosphorylation , Protein Processing, Post-Translational , Response Elements , Transcription, Genetic , Up-Regulation , p38 Mitogen-Activated Protein Kinases/metabolism
5.
Mol Cell Biochem ; 352(1-2): 155-62, 2011 Jun.
Article in English | MEDLINE | ID: mdl-21360282

ABSTRACT

The dual-specificity phosphatase (DUSP) 13 gene encodes two atypical DUSPs, DUSP13B/TMDP and DUSP13A/MDSP using alternative exons. DUSP13B protein is most highly expressed in testis, particularly in spermatocytes and round spermatids of the seminiferous tubules, while that of DUSP13A is restricted to skeletal muscle. Here, we show that DUSP13B inactivated MAPK activation in the order of selectivity, JNK = p38>ERK in cells, while DUSP13A did not show MAPK phosphatase activity. Reporter gene analysis showed that DUSP13B had significant inhibitory effect on AP-1-dependent gene expression, but DUSP13A did not. To our knowledge, DUSP13B is the first identified testis-specific phosphatase that inhibits stress-activated MAPKs. These data suggest an important role for DUSP13B in protection from external stress during spermatogenesis.


Subject(s)
Dual-Specificity Phosphatases/physiology , Gene Expression Regulation/physiology , Mitogen-Activated Protein Kinases/metabolism , Transcription Factor AP-1/physiology , Animals , Cell Line , Enzyme Activation , Exons , Humans , Mitogen-Activated Protein Kinases/antagonists & inhibitors , Protein Kinase Inhibitors/pharmacology
6.
Dev Cell ; 18(5): 763-74, 2010 May 18.
Article in English | MEDLINE | ID: mdl-20493810

ABSTRACT

Earlier, we reported that S6K1(-/-) mice have reduced body fat mass, have elevated rates of lipolysis, have severely decreased adipocyte size, and are resistant to high fat diet (HFD)-induced obesity. Here we report that adipocytes of S6K1(-/-) mice on a HFD have the capacity to increase in size to a degree comparable to that of wild-type (WT) mice, but not in number, indicating an unexpected lesion in adipogenesis. Tracing this lesion revealed that S6K1 is dispensable for terminal adipocyte differentiation, but is involved in the commitment of embryonic stem cells to early adipocyte progenitors. We further show that absence of S6K1 attenuates the upregulation of transcription factors critical for commitment to adipogenesis. These results led to the conclusion that a lack of S6K1 impairs the generation of de novo adipocytes when mice are challenged with a HFD, consistent with a reduction in early adipocyte progenitors.


Subject(s)
Adipocytes/cytology , Cell Differentiation/physiology , Ribosomal Protein S6 Kinases, 70-kDa/genetics , Ribosomal Protein S6 Kinases, 90-kDa/genetics , Ribosomal Protein S6 Kinases, 90-kDa/physiology , Adipocytes/pathology , Adipogenesis/genetics , Adipogenesis/physiology , Adipose Tissue, White/anatomy & histology , Animals , Humans , Hyperplasia/genetics , Male , Mice , Mice, Knockout , Obesity/genetics , Obesity/prevention & control , RNA, Messenger/genetics
7.
Biochem Biophys Res Commun ; 393(2): 201-6, 2010 Mar 05.
Article in English | MEDLINE | ID: mdl-20122898

ABSTRACT

MAPK phosphatase-7 (MKP-7) was identified as a JNK-specific phosphatase. However, despite its high specificity for JNK, MKP-7 interacts also with ERK. We previously showed that as a physiological consequence of their interaction, activated ERK phosphorylates MKP-7 at Ser-446, and stabilizing MKP-7. In the present study, we analyzed MKP-7 function in activation of ERK. A time-course experiment showed that both MKP-7 and its phosphatase-dead mutant prolonged mitogen-induced ERK phosphorylation, suggesting that MKP-7 functions as a scaffold for ERK. An important immunohistological finding was that nuclear translocation of phospho-ERK following PMA stimulation was blocked by co-expressed MKP-7 and, moreover, that phospho-ERK co-localized with MKP-7 in the cytoplasm. Reporter gene analysis indicated that MKP-7 blocks ERK-mediated transcription. Overall, our data indicate that MKP-7 down-regulates ERK-dependent gene expression by blocking nuclear accumulation of phospho-ERK.


Subject(s)
Cytoplasm/enzymology , Dual-Specificity Phosphatases/metabolism , Extracellular Signal-Regulated MAP Kinases/metabolism , Mitogen-Activated Protein Kinase Phosphatases/metabolism , Transcriptional Activation , Active Transport, Cell Nucleus , Animals , COS Cells , Cell Nucleus/enzymology , Chlorocebus aethiops , Down-Regulation , Epidermal Growth Factor/pharmacology , Humans , Phosphorylation , Ribosomal Protein S6 Kinases, 90-kDa/metabolism
8.
J Biol Chem ; 280(15): 14716-22, 2005 Apr 15.
Article in English | MEDLINE | ID: mdl-15689616

ABSTRACT

MAPK cascades can be negatively regulated by members of the MAPK phosphatase (MKP) family. However, how MKP activity is regulated is not well characterized. MKP-7, a JNK-specific phosphatase, possesses a unique COOH-terminal stretch (CTS) in addition to domains conserved among MKP family members. The CTS contains several motifs such as a nuclear localization signal, a nuclear export signal, PEST sequences, and a serine residue (Ser-446) that can be phosphorylated by activated ERK, suggesting an important regulatory role(s).(35)S-pulse labeling experiments indicate that the half-life of MKP-7 is 1.5 h, a period significantly elongated by deleting the CTS. We also show that overexpressed MKP-7 is polyubiquitinated when co-expressed with ubiquitin and that proteasome inhibitors markedly inhibit MKP-7 degradation. We also determined that MKP-7 phosphorylated at Ser-446 has a longer half-life than unphosphorylated form of the wild type protein, as does a phospho-mimic mutant of MKP-7. These results indicate that activation of the ERK pathway strongly blocks JNK activation through stabilization of MKP-7 mediated by phosphorylation.


Subject(s)
Protein Tyrosine Phosphatases/chemistry , Serine/chemistry , Amino Acid Motifs , Animals , COS Cells , Cell Nucleus/metabolism , DNA/metabolism , Dual-Specificity Phosphatases , Enzyme Activation , Extracellular Signal-Regulated MAP Kinases/metabolism , Gene Deletion , Humans , Immunoblotting , Immunohistochemistry , JNK Mitogen-Activated Protein Kinases/metabolism , MAP Kinase Kinase 4 , Mitogen-Activated Protein Kinase Kinases/metabolism , Mitogen-Activated Protein Kinase Phosphatases , Models, Biological , Phosphorylation , Plasmids/metabolism , Protein Structure, Tertiary , Protein Tyrosine Phosphatases/metabolism , Time Factors , Transfection , Ubiquitin/metabolism
9.
Biochem J ; 383(Pt. 3): 447-55, 2004 Nov 01.
Article in English | MEDLINE | ID: mdl-15281913

ABSTRACT

We have isolated a mouse cDNA for a novel dual-specificity phosphatase designated LDP-3 (low-molecular-mass dual-specificity phosphatase 3). The 450 bp open reading frame encodes a protein of 150 amino acids with a predicted molecular mass of 16 kDa. Northern blot and reverse transcription-PCR analyses show that LDP-3 transcripts are expressed in almost all mouse tissues examined. In vitro analyses using several substrates and inhibitors indicate that LDP-3 possesses intrinsic dual-specificity phosphatase activity. When expressed in mammalian cells, LDP-3 protein is localized mainly to the apical submembrane area. Forced expression of LDP-3 does not alter activation of ERK (extracellular-signal-regulated kinase), but rather enhances activation of JNK (c-Jun N-terminal kinase) and p38 and their respective upstream kinases MKK4 (mitogen-activated protein kinase kinase 4) and MKK6 in cells treated with 0.4 M sorbitol. By screening with a variety of stimuli, we found that LDP-3 specifically enhances the osmotic stress-induced activation of JNK and p38.


Subject(s)
JNK Mitogen-Activated Protein Kinases/metabolism , Protein Tyrosine Phosphatases/chemistry , Protein Tyrosine Phosphatases/physiology , p38 Mitogen-Activated Protein Kinases/metabolism , Amino Acid Sequence , Animals , COS Cells/enzymology , Cell Line , Chlorocebus aethiops , Dual-Specificity Phosphatases , Enzyme Activation/genetics , Enzyme Activation/physiology , Humans , MAP Kinase Kinase Kinase 4/metabolism , Mice , Mitogen-Activated Protein Kinase 6/metabolism , Molecular Sequence Data , Molecular Weight , Mutation/genetics , Mutation/physiology , Osmotic Pressure , Protein Tyrosine Phosphatases/genetics , Substrate Specificity , Transfection/methods
10.
J Biol Chem ; 278(34): 32448-56, 2003 Aug 22.
Article in English | MEDLINE | ID: mdl-12794087

ABSTRACT

We previously showed that MKP-7 suppresses MAPK activation in COS-7 cells in the order of selectivity, JNK >> p38 > ERK, but interacts with ERK as well as JNK and p38. In this study we found that, when expressed in COS-7 cells with HA-ERK2, the mobility of FLAG-MKP-7 was decreased on SDS-PAGE gels depending on several stimuli, including phorbol 12-myristate 13-acetate, fetal bovine serum, epidermal growth factor, H2O2, and ionomycin. By using U0126, a MEK inhibitor, and introducing several point mutations, we demonstrated that this upward mobility shift is because of phosphorylation and identified Ser-446 of MKP-7 as the phosphorylation site targeted by ERK activation. To determine how MKP-7 interacts with MAPKs, we identified three domains in MKP-7 required for interaction with MAPKs, namely, putative MAP kinase docking domains (D-domain) I and II and a long COOH-terminal stretch unique to MKP-7. The D-domain I is required for interaction with ERK and p38, whereas the D-domain II is required for interaction with JNK and p38, which is likely to be important for MKP-7 to suppress JNK and p38 activations. The COOH-terminal stretch of MKP-7 was shown to determine JNK preference for MKP-7 by masking MKP-7 activity toward p38 and is a domain bound by ERK. These data strongly suggested that Ser-446 of MKP-7 is phosphorylated by ERK.


Subject(s)
Mitogen-Activated Protein Kinases/metabolism , Protein Tyrosine Phosphatases/metabolism , Serine/metabolism , Amino Acid Sequence , Animals , COS Cells , Catalysis , Dual-Specificity Phosphatases , HeLa Cells , Humans , Mitogen-Activated Protein Kinase Phosphatases , Molecular Sequence Data , Phosphorylation , Protein Tyrosine Phosphatases/chemistry , Sequence Homology, Amino Acid
SELECTION OF CITATIONS
SEARCH DETAIL
...